Skip to main content
. 2023 Oct 4;9(4):20552173231204466. doi: 10.1177/20552173231204466

Table 4.

The duration of washout and number of relapses during the first 6 months and 12 months after discontinuation of natalizumab. The results are presented for the total study cohort, n (%).

Number of relapses 6 months follow-upa
(n = 538)
12 months follow-upb
(n = 519)
< 6 weeks washout (n = 107) ≥ 6 weeks washout (n = 432) < 6 weeks washout (n = 98) ≥ 6 weeks washout (n = 422)
0 93 (87%) 317 (73%) 79 (81%) 271 (64%)
1 12 (11%) 88 (20%) 13 (13%) 88 (21%)
2+ 2 (2%) 27 (6%) 6 (6%) 63 (15%)
a

A statistically significant difference (p = 0.012) was detected in the frequency of relapses between patients with a washout duration of less than 6 weeks and patients with a washout duration of 6 weeks or more, using Fisher's exact test.

b

A statistically significant difference (p = 0.005) was detected in the frequency of relapses between patients who had a washout duration of less than 6 weeks and patients who had a washout duration of 6 weeks or more, using Fisher's exact test.